Full Breakdown
Study Shows 30-Year Cardiovascular Risk Prediction for Women Using Routine Blood Tests
5/10/2026, 10:23:05 PM
Long-Term Risk Prediction from Three Biomarkers
Researchers examined 27,939 women from the Women’s Health Initiative, using baseline LDL-C, hsCRP and lipoprotein(a) measured in 1992-95. Women with all three markers in the top quartile faced 2.6-fold higher major cardiovascular events and 3.7-fold higher stroke risk over the next thirty years. The markers were independent, each indicating a distinct disease pathway.
Current Guidelines vs. Early Assessment
Current guidelines advise starting preventive drugs for women only after age 60-70, based on 5- or 10-year risk scores. The new thirty-year model suggests high-risk women could be identified a decade earlier, prompting calls to revise guidelines.
Study Design and Risk Multipliers
The analysis used baseline blood draws from the long-term U.S. cohort, adjusting for age, smoking and hypertension. The combined elevation of LDL-C, hsCRP and lipoprotein(a) produced the reported 2.6- and 3.7-fold risk increases, demonstrating additive predictive value.
Clinical and Pharmaceutical Implications
Each biomarker points to a different therapeutic target: statins for LDL-C, anti-inflammatory agents for hsCRP, and experimental lipoprotein(a)-lowering drugs from Novartis, Amgen, Eli Lilly and Silence Therapeutics. Lifestyle measures such as exercise and smoking cessation were also highlighted.
Diversity, Screening Recommendations and Gaps
The cohort was largely white, limiting direct extrapolation to Black and Hispanic women, who have higher rates of undetected inflammation. Investigators called for universal hsCRP and lipoprotein(a) screening alongside cholesterol, noting potential disproportionate benefit. Evidence that early treatment improves outcomes remains to be demonstrated.
Official Statements from Study Leadership
Dr. Paul Ridker said waiting until the sixth or seventh decade to consider preventive therapy is outdated. He urged a shift to thirty-year risk assessment and broader biomarker use to guide individualized treatment.
Verbatim Quotes
- “This is good for patients first and foremost, but it is also important information for (manufacturers of) cholesterol lowering drugs, anti-inflammatory drugs, and lipoprotein(a)lowering drugs - the implications for therapy are broad,” — Dr. Paul Ridker, Brigham and Women’s Hospital
- “suggest to physicians that women should generally not be considered for preventive therapies until their 60s and 70s. These new data… clearly demonstrate that our guidelines need to change,” — Dr. Paul Ridker, Brigham and Women’s Hospital
- “We must move beyond discussions of 5 or 10 year risk.” — Dr. Paul Ridker, Brigham and Women’s Hospital
- “The three biomarkers are fully independent of each other and tell us about different biologic issues each individual woman faces,” — Dr. Paul Ridker, Brigham and Women’s Hospital
What’s Next
The data were presented at the European Society of Cardiology meeting in London and published in *The New England Journal of Medicine*. Ongoing trials of lipoprotein(a)-lowering agents will report efficacy, and societies are reviewing the evidence for possible guideline updates.
